natgillin/translations-raw huggingface dataset:
A reliable method of barrier contraception must be used in addition to hormonal contraceptives (see section 4.6).
Osim hormonskih kontraceptiva mora se koristiti i pouzdana metoda barijerne kontracepcije (vidjeti dio 4.6).
Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Istodobna primjena tenofovirdizoproksila i didanozina dovodi do povećanja sistemske izloženosti didanozinu od 40-60%, što može povećati rizik od nuspojava povezanih s didanozinom.
In 35 patients receiving efavirenz 600 mg once daily, steady-state peak concentration (Cmax) was 12.9 ± 3.7 µM (29%) [mean ± standard deviation (S.D.) (coefficient of variation (%CV))], steady-state Cmin was 5.6 ± 3.2 µM (57%), and AUC was 184 ± 73 µM•h (40%).
U 35 bolesnika koji su primali 600 mg efavirenza jednom dnevno, vršna vrijednost koncentracije (Cmax) u stanju dinamičke ravnoteže bila je 12,9 ± 3,7 µM (29%) [srednja vrijednost ± standardna devijacija (SD) (koeficijent varijacije (%CV))], Cmin u stanju dinamičke ravnoteže 5,6 ± 3,2 µM (57%) i AUC 184 ± 73 µM•h (40%).
Tenofovir disoproxil (n=45)
tenofovirdizoproksil (n=45)
Pharmacokinetic parameters were determined following administration of single doses of the individual preparations of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment.
Farmakokinetički parametri određeni su uglavnom nakon primjene jednokratnih doza pojedinačnih formulacija od 200 mg emtricitabina ili 245 mg tenofovirdizoproksila kod bolesnika koji nisu bili inficirani virusom HIV-a, a imali su različiti stupanj oštećenja funkcije bubrega.
Uncommon rhabdomyolysis2, muscular weakness2
Manje često rabdomioliza2, mišićna slabost2
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
U bolesnika s uznapredovalom bolesti jetre ili cirozom jetre ne preporučuje se prekid liječenja, jer egzacerbacija hepatitisa nakon liječenja može dovesti do dekompenzacije jetre.
Caution must be taken in any patient with a history of seizures.
Oprez je potreban kod svih bolesnika s napadajima u anamnezi.
Atripla is not recommended for patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome) while taking an NNRTI.
Uzimanje Atriple ne preporučuje se bolesnicima u kojih se tijekom uzimanja NNRTI lijekova pojavila po život opasna kožna reakcija (npr. Stevens-Johnsonov sindrom).
Rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have also been reported.
Zabilježeni su i su rijetki slučajevi oštećenja bubrega, zatajenja bubrega i manje česti slučajevi proksimalne bubrežne tubulopatije (uključujući Fanconijev sindrom), što je ponekad dovelo do abnormalnosti kostiju (rijetko pridonoseći nastanku prijeloma).
Atripla must not be used in patients with severe hepatic impairment (see section 4.3) and is not recommended for patients with moderate hepatic impairment.
Atripla se ne smije davati bolesnicima s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
In patients with a history of renal dysfunction or in patients who are at risk of renal dysfunction, a more frequent monitoring of renal function is required.
U bolesnika s anamnezom bubrežne disfunkcije ili rizikom od poremećaja funkcije bubrega potrebno je češće pratiti funkciju bubrega.
- Independent of a history of liver disease, your doctor will consider regular blood tests to check how your liver is working.
Bez obzira jeste li ili niste do sada imali bolesti jetre, liječnik će razmotriti potrebu za redovitim krvnim pretragama da bi se utvrdilo kako Vaša jetra radi.
If you notice any symptoms of infection, please tell your doctor at once.
Ako opazite bilo koji od simptoma infekcije, odmah o tome obavijestite liječnika.
If you do miss a dose of Atripla within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time.
Ako ipak propustite uzeti jednu dozu Atriple, a to ste primijetili prije nego je proteklo 12 sati od vremena kada Atriplu obično uzimate, uzmite dozu čim možete, a potom sljedeću dozu uzmite u redovito vrijeme.
Atripla is contraindicated in patients with severe hepatic impairment (see section 4.3) and not recommended in patients with moderate hepatic impairment.
Atripla je kontraindicirana u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
Since Atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered (see section 4.5).
Budući da je Atripla kombinirani lijek s fiksnim dozama, doza efavirenza ne može se mijenjati (vidjeti dio 4.5).
If the patient vomits more than 1 hour after taking Atripla he/she does not need to take another dose.
Ako bolesnik povraća nakon više od 1 sata od uzimanja Atriple, nije potrebno uzeti još jednu dozu.
Gastrointestinal disorders: Very common diarrhoea, nausea diarrhoea, vomiting, nausea
Poremećaji probavnog sustava: Vrlo često proljev, mučnina proljev, povraćanje, mučnina
Stevens-Johnson syndrome, erythema multiforme3, severe rash angioedema4
Stevens-Johnsonov sindrom, multiformni eritem3, težak osip (< 1%)
Co-administration of ritonavir at doses of 600 mg and Atripla is not recommended.
Ne preporučuje se istodobna primjena ritonavira u dozama od 600 mg s Atriplom.
Co-administration of Atripla with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir.
Istodobna primjena Atriple i elbasvira/grazoprevira kontraindicirana je jer može dovesti do gubitka virološkog odgovora na elbasvir/grazoprevir.
Discontinuation of Atripla therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Prekid liječenja Atriplom u bolesnika istodobno inficiranih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa.
A multiple-dose study of efavirenz showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh-Turcotte Class A) compared with controls.
U ispitivanju efavirenza s primjenom višestrukih doza nisu utvrđeni značajni učinci na farmakokinetiku efavirenza u bolesnika s blagim oštećenjem jetre (stadij A Child-Pugh-Turcotte) u usporedbi s kontrolnom skupinom.
If a patient is already taking St. John's wort, stop St. John's wort, check viral levels and if possible efavirenz levels.
Ako bolesnik već uzima gospinu travu, treba prestati s njezinim uzimanjem te se moraju provjeriti razine virusa i, ako je moguće, razine efavirenza.
A similar reduction in indinavir exposures was observed when indinavir 1,000 mg q8h was given with efavirenz 600 mg q.d.
Slično smanjenje izloženosti indinaviru uočeno je kada je indinavir u dozi 1000 mg q8h davan zajedno s efavirenzom u dozi 600 mg q.d. (indukcija CYP3A4)
The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil, administered separately in HIV infected patients.
Zasebni farmaceutski oblici efavirenza, emtricitabina i tenofovirdizoproksila korišteni su da bi se utvrdila farmakokinetika efavirenza, emtricitabina i tenofovirdizoproksila koji su zasebno davani bolesnicima inficiranima virusom HIV-a.
If you are taking any of these medicines, tell your doctor immediately.
Uzimate li bilo koji od tih lijekova, bez odlaganja to recite svojem liječniku.
• allergic reaction (hypersensitivity) that may cause severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, see section 2)
• alergijska reakcija (preosjetljivost) koja može uzrokovati teške reakcije na koži (Stevens
No malformations were observed in foetuses from efavirenz-treated rats and rabbits.
Nisu uočene malformacije zametaka u štakora i kunića koji su primali efavirenz.
Atripla should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.
Atripla se ne smije primjenjivati istodobno s adefovirdipivoksilom ili s lijekovima koji sadrže tenofoviralafenamid.
Elbasvir/grazoprevir: Co-administration of Atripla with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir (see section 4.3 and Table 1).
Elbasvir/grazoprevir: Istodobna primjena Atriple i elbasvira/grazoprevira kontraindicirana je jer može dovesti do gubitka virološkog odgovora na elbasvir/grazoprevir (vidjeti dio 4.3 i tablicu 1).
A single 245 mg dose of tenofovir disoproxil was administered to non-HIV infected patients with varying degrees of hepatic impairment defined according to CPT classification.
Jednokratna doza od 245 mg tenofovirdizoproksila dana je bolesnicima koji nisu bili inficiranih virusom HIV-a, a imali su različit stupanj oštećenja funkcije jetre prema klasifikaciji CPT.
In a 144-week open-label randomised clinical study (GS-01-934) antiretroviral treatment-naïve HIV-1 infected patients received either a once-daily regimen of efavirenz, emtricitabine and tenofovir disoproxil or a fixed combination of lamivudine and zidovudine (Combivir) administered twice daily and efavirenz once daily (please refer to the Summary of Product Characteristics for Truvada).
U otvorenom randomiziranom kliničkom ispitivanju (GS-01-934) u trajanju od 144 tjedana, bolesnici inficirani virusom HIV-1 koji prije nisu bili liječeni antiretrovirusnom terapijom primali su ili efavirenz, emtricitabin i tenofovirdizoproksil po režimu doziranja jedanput na dan ili fiksnu kombinaciju lamivudina i zidovudina (Combivir) davanu dva puta na dan te efavirenz jedanput na dan (pročitajte sažetak opisa svojstava lijeka za Truvadu).
Atripla and vigabatrin or gabapentin can be coadministered without dose adjustment.
Atripla i vigabatrin ili gabapentin mogu se primjenjivati istodobno bez prilagođavanja doze.
Rare completed suicide3,4, delusion3,4, neurosis3,4 Nervous system disorders: Very common headache dizziness
Rijetko izvršeno samoubojstvo3,4, deluzija3,4, neuroza3,4
• inflammation of the kidney, passing a lot of urine and feeling thirsty
• upala bubrega, mokrenje velikih količina mokraće i osjećaj žeđi
St. John's wort (Hypericum perforatum): Co-administration of Atripla and St. John's wort or herbal preparations containing St. John's wort is contraindicated.
Gospina trava (Hypericum perforatum): Istodobna primjena Atriple i gospine trave ili biljnih pripravaka koji sadržavaju gospinu travu je kontraindicirana.
Co-administration with other medicinal products
Istodobna primjena s drugim lijekovima
In the prior-NNRTI stratum, response rates were 98.9% vs 97.4% for Atripla and SBR patients respectively; a difference (95%CI) of 1.4% (-4.0%, 6.9%)].
U skupini bolesnika koji su prethodno liječeni NNRTI lijekovima stope odgovora bile su 98,9% u bolesnika koji su primali Atriplu u usporedbi s 97,4% u SBR bolesnika: razlika (95%CI) od 1,4% (-4,0%, 6,9%)].
Concomitant use of Ginkgo biloba extracts is not recommended (see section 4.5).
Ne preporučuje se istodobna primjena ekstrakta Ginkgo bilobe (vidjeti dio 4.5).
Artemether/Lumefantrine/Efavirenz (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg q.d.)
Antimalarici artemeter/lumefantrin/efavirenz (tableta od 20/120 mg, 6 doza po 4 tablete tijekom 3 dana/600mg q.d.)
Serious birth defects have been seen in unborn animals and in the babies of women treated with efavirenz during pregnancy.
U nerođenih životinja i djece žena koje su tijekom trudnoće uzimale efavirenz zabilježeni su ozbiljne urođene mane.
Due to similarities with emtricitabine, Atripla should not be administered concomitantly with other cytidine analogues, such as lamivudine (see section 4.5).
Zbog sličnosti s emtricitabinom, Atripla se ne smije primjenjivati zajedno s drugim analozima citidina, kao što je lamivudin (vidjeti dio 4.5).
Implant: Etonogestrel/Efavirenz
Implantat: etonogestrel/efavirenz
Pregnancy should be avoided in women receiving Atripla.
Žene koje primaju Atriplu trebaju izbjegavati trudnoću.
Carbamazepine:
karbamazepin:
ANTI-INFECTIVES HIV antivirals
ANTIINFEKTIVNI LIJEKOVI
Co-administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following co-administration with efavirenz leading to reduced therapeutic effect of sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
Istodobna primjena Atriple i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira se ne preporučuje jer se očekuje da će se koncentracija velpatasvira i voksilaprevira u plazmi smanjiti nakon istodobne primjene s efavirenzom što će dovesti do smanjenog terapijskog učinka sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira (vidjeti dio 4.5).
- Medicines used to treat convulsions/seizures (anticonvulsants): Carbamazepine, phenytoin,
- Lijekovi koji se koriste za liječenje konvulzija/napadaja (antikonvulzivi): karbamazepin, fenitoin, fenobarbital.
While the clinical significance of decreased indinavir concentrations has not been established, the magnitude of the observed pharmacokinetic interaction should be taken into consideration when choosing a regimen containing both efavirenz, a component of Atripla, and indinavir.
Iako nije ustanovljen klinički značaj smanjenih koncentracija indinavira, prilikom odabira režima koji sadrži i komponentu Atriple efavirenz i indinavir nužno je uzeti u obzir opseg farmakokinetičke interakcije.
• pain in the abdomen (stomach), caused by inflammation of the pancreas
• bol u trbuhu prouzrokovana upalom gušterače
Elderly patients are more likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Atripla (see section 4.2).
Kod starijih je osoba veća vjerojatnost da imaju smanjenu funkciju jetre ili bubrega pa je stoga nužan oprez kad se starije osobe liječe Atriplom (vidjeti dio 4.2).
-0.5% (-3.2% to 2.2%)
-0,5% (-3,2% do 2,2%)
AUC: ↔* (↓ 9% to ↑ 10%) Cmax: ↑ 17%* (↑ 8 to ↑ 27) Cmin: ↓ 42%* (↓ 31 to ↓ 51)
AUC: ↔* (↓ 9% do ↑ 10%) Cmax: ↑ 17%* (↑ 8 do ↑ 27) Cmin: ↓ 42%* (↓ 31 do ↓ 51)
Eye disorders: Uncommon vision blurred
Poremećaji oka: Manje često zamućen vid
There were no clinically significant pharmacokinetic interactions when emtricitabine was administered with stavudine, zidovudine or famciclovir.
Nema klinički značajnih farmakokinetičkih interakcija kada se emtricitabin primjenjuje zajedno sa stavudinom, zidovudinom ili famciklovirom.
Following multiple dose oral administration of emtricitabine to 20 HIV infected patients, steady-state Cmax was 1.8 ± 0.7 µg/ml (mean ± S.D.) (39%CV), steady-state Cmin was 0.09 ± 0.07 µg/ml (80%) and the AUC was 10.0 ± 3.1 µg•h/ml (31%) over a 24 hour dosing interval.
Nakon peroralnog davanja višekratnih doza emtricitabina 20 bolesnika inficiranih HIV-om, u 24-satnom intervalu doziranja vrijednosti Cmax u stanju dinamičke ravnoteže bile su 1,8 ± 0,7 µg/ml (srednja vrijednost ± SD) (39% CV), Cmin u stanju dinamičke ravnoteže 0,09 ± 0,07 µg/ml (80%) i AUC 10,0 ± 3,1 µg•h/ml (31%).
Proguanil:
progvanil:
Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).
Prije započinjanja prvog režima antiretrovirusnog liječenja, bolesnici nisu smjeli doživjeti virološki neuspjeh na bilo koju raniju antiretrovirusnu terapiju i mora biti ustanovljeno da nisu nosili sojeve virusa s mutacijama koje pokazuju značajnu rezistenciju na bilo koju od tri komponente koje sadržava Atripla (vidjeti dio 4.4 i
Since Atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Atripla must not be co-administered (see section 4.3 and Table 1).
Budući da je Atripla lijek s kombinacijom fiksnih doza, doza efavirenza se ne može mijenjati, što znači da se vorikonazol i Atripla ne smiju primjenjivati istodobno (vidjeti dio 4.3 i Tablicu 1).
Co-administration of Atripla and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Ne preporučuje se istodobna primjena Atriple i didanozina jer se izloženost didanozinu značajno povećava u slučaju istodobne primjene tenofovirdizoproksila, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
It is recommended that Atripla be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Preporučuje se uzimanje Atriple na prazan želudac jer hrana može povećati izloženost efavirenzu i može dovesti do povećane učestalosti nuspojava (vidjeti dio 4.4 i 4.8).
Common pruritus vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)1
Često pruritus vezikulobulozni osip, pustulozni osip, makulopapulozni osip, osip, pruritus, urtikarija, promjena boje kože (pojačana pigmentacija)1
• decreases in phosphate levels in the blood
• smanjene razine fosfata u krvi
(CYP3A4 induction) The increase in efavirenz pharmacokinetic parameters is not considered clinically significant.
Povećanje parametara farmakokinetike efavirenza ne smatra se klinički značajnim.
Psychiatric adverse reactions have been reported in patients treated with efavirenz.
Postoje izvješća o psihijatrijskim nuspojavama u bolesnika koji su uzimali efavirenz.
As a fixed combination, Atripla should not be administered concomitantly with other medicinal products containing the same active components, emtricitabine or tenofovir disoproxil.
Atripla se, kao fiksna kombinacija, ne smije primjenjivati istodobno s drugim lijekovima koji sadržavaju iste djelatne komponentne, emtricitabin ili tenofovirdizoproksil.
Concomitant use of Ginkgo biloba extracts is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena ekstrakta Ginkgo bilobe (vidjeti dio 4.4).
Concomitant administration of simeprevir with efavirenz, a component of Atripla, resulted in significantly decreased plasma concentrations of simeprevir due to CYP3A induction by efavirenz, which may result in loss of therapeutic effect of simeprevir.
sastojkom Atriple, rezultirala je značajno smanjenim koncentracijama simeprevira u plazmi zbog indukcije CYP3A efavirenzom, što može dovesti do gubitka terapijskog učinka simeprevira.
Simeprevir/Emtricitabine
simeprevir/emtricitabin
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Bolesnici s otprije postojećim poremećajem funkcije jetre, uključujući kronični aktivni hepatitis, imaju povećanu učestalost abnormalnosti funkcije jetre tijekom kombinirane antiretrovirusne terapije (engl.
Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir: Co-administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended (see section 4.4 and Table 1)
Sofosbuvir/velpatasvir i sofosbuvir/velpatasvir/voksilaprevir: ne preporučuje se istodobna primjena Atriple i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira (vidjeti dio 4.4 i Tablicu 1)
- if you are allergic to efavirenz, emtricitabine, tenofovir, tenofovir disoproxil or any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Atriplu - ako ste alergični na efavirenz, emtricitabin, tenofovir, tenofovirdizoproksil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako bolujete od teške bolesti jetre.
When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to Atripla [92.4% versus 94.0% for the PVR (sensitivity analysis) for Atripla and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%).
Zasebna analiza dviju skupina pokazala je da su u skupini koja je prethodno liječena inhibitorima proteaze stope odgovora numerički manje u bolesnika koji su prešli na Atriplu [PVR (analiza osjetljivosti) od 92,4% u bolesnika koji su primali Atriplu u usporedbi s 94,0% u SBR bolesnika: razlika (95%CI) od -1,6% (-10,0%, 6,7%).
0.5% (-7.0% to 9.3%)
0,5% (-7,0% do 9,3%)
Uncommon hepatitis acute
Manje često akutni hepatitis
The mean (%CV) tenofovir exposure increased from 2,185 ng•h/ml (12%) in patients with normal renal function, to 3,064 ng•h/ml (30%), 6,009 ng•h/ml (42%) and 15,985 ng•h/ml (45%) in patients with mild, moderate and severe renal impairment, respectively.
Srednja je vrijednost (% koeficijenta varijacije, CV) izloženosti tenofoviru porasla s 2185 (12%) ng•h/ml u ispitanika s normalnom funkcijom bubrega na 3064 (30%) ng•h/ml, 6009 (42%) ng•h/ml i 15 985 (45%) ng•h/ml, u bolesnika s blagim, umjerenim odnosno teškim oštećenjem funkcije bubrega.
Co-administration of Atripla and didanosine is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena Atriple i didanozina (vidjeti dio 4.4).
Exacerbations of hepatitis after discontinuation of treatment: In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis may occur after discontinuation of treatment (see section 4.4).
Egzacerbacije hepatitisa nakon prekida liječenja: U bolesnika s HIV-om koji su istodobno imali infekciju HBV-om, nakon prekida liječenja mogući su klinički i laboratorijski znakovi hepatitisa. (vidjeti dio 4.4).
Non-sustained convulsions were observed in some monkeys receiving efavirenz for ≥ 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose.
Kod nekih majmuna, koji su primali efavirenz ≥ 1 godinu, opažene su prolazne konvulzije u slučaju davanja doza uz koje je dosegnuta 4 do 13 puta veća vrijednost AUC nego kod ljudi koji su primali preporučenu dozu.
Interaction not studied with efavirenz, emtricitabine, or tenofovir disoproxil.
Nije ispitana interakcija s efavirenzom, emtricitabinom niti tenofovirdizoproksilom.
The administration of Atripla with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in frequency of adverse reactions (see section 4.8).
Uzimanje Atriple s hranom može povećati izloženost efavirenzu (vidjeti dio 5.2) te može dovesti do povećane učestalosti nuspojava (vidjeti dio 4.8).
Concomitant administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir.
Očekuje se da će istodobna primjena Atriple i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/ voksilaprevira smanjiti koncentraciju velpatasvira i voksilaprevira u plazmi.
• back pain caused by kidney problems, including kidney failure.
• bolovi u leđima prouzročeni problemima s bubrezima, uključujući zatajenje bubrega.
AUC: ↓ 43% (↓ 7 to ↓ 65) Cmax: ↔
AUC: ↓ 43% (↓ 7 do ↓ 65) Cmax: ↔
Recommendation concerning co-administration with Atripla (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Preporuka za istodobnu primjenu s Atriplom (efavirenz 600 mg, emtricitabin 200 mg, tenofovirdizoproksil 245 mg)
AUC: ↓ 31% (↓ 8 to ↓ 47) Cmin: ↓ 40%
AUC: ↓ 31% (↓ 8 do ↓ 47) Cmin: ↓ 40%
Uncommon hypersensitivity
Manje često preosjetljivost
Atovaquone:
atovakvon:
Atripla can reduce the amount of itraconazole or posaconazole in your blood.
Atripla može smanjiti količinu itrakonazola ili posakonazola u krvi.